세계의 증후군 멀티플렉스 패널 시장 : 전략과 동향 - 증후군별, 장소별, 제품별, 국가별 예측 : 시장 분석 및 주요 가이드 첨부(2025-2029년)

Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2025 to 2029

US $ 6,995 ￦ 9,633,000

PDF (Single User License)

PDF 보고서를 1명(One device)만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,495 ￦ 14,453,000

PDF (Five User License)

PDF 보고서를 동일 사업장의 5명(Five devices)까지 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 13,995 ￦ 19,273,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

이 보고서는 세계의 증후군 멀티플렉스 패널 시장을 조사했으며, 시장 개요와 함께 증후군별, 위치별, 제품별, 국가별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 시장 가이드

제2장 소개와 시장 정의

• 증후군 멀티플렉스 패널이란 무엇인가
• 증후군 검사 - 진단에서 조용한 혁명
• 시장의 정의
• 조사 방법
• 관점: 헬스케어와 IVD 업계

제3장 감염증

• 감염증- 전체상
• 병원체
• 증상과 증후군
• 질병
• 감염
• 감염증 진단
• 감염증의 정의
• 증후군성 감염증

제4장 업계 개요

• 시장 진입기관
  • 학술연구기관
  • 진단 시험 개발자
  • 계장 공급자
  • 약품 및 시약 제조업체
  • 병리 공급자
  • 독립계 임상 실험실
  • 공공의 국립/지역 연구소
  • 병원 검사실
  • 임상 실험실
  • 감사기관
  • 인증기관
• 임상 검사 시장의 부문
• 산업 구조

제5장 시장 동향

• 성장 촉진요인
• 성장 억제요인
• 계측, 자동화, 진단의 동향

제6장 증후군 검사의 최근 동향

제7장 주요 기업 프로파일

• Abacus Diagnostica
• Abbott Laboratories
• Accelerate Diagnostics
• Ador Diagnostics
• ADT Biotech
• Akonni Biosystems
• Alveo Technologies
• Antelope Dx
• Applied BioCode
• Aureum Diagnostics
• Aus Diagnostics
• Baebies
• Beckman Coulter Diagnostics
• Becton, Dickinson and Company
• Binx Health
• Biocartis
• BioFire Diagnostics(bioMerieux)
• bioMerieux Diagnostics
• Bio-Rad Laboratories, Inc
• Bosch Healthcare Solutions GmbH
• Cepheid(Danaher)
• Credo Diagnostics Biomedical
• Cue Health
• Curetis NV/Curetis GmbH
• Detect
• Diagenode Diagnostics
• Diasorin SpA
• Domus Diagnostics
• Enzo Biochem
• Eurofins Scientific
• Fluxergy
• Fusion Genomics.
• Genetic Signatures
• GenMark Dx(Roche)
• Grip Molecular Technologies
• Hibergene Diagnostics
• Hologic
• Immunexpress
• Inflammatix
• Invetech
• Janssen Diagnostics
• Karius
• Lexagene
• LightDeck Diagnostics
• Lucira Health
• Luminex Corp(DiaSorin)
• Maxim Biomedical
• Meridian Bioscience
• Mesa Biotech(Thermo Fisher)
• MicroGem
• Millipore Sigma
• Minute Molecular
• Mobidiag(Hologic)
• Molbio Diagnostics
• Nanomix
• Novel Microdevices
• OnsiteGene
• Operon
• Oxford Nanopore Technologies
• Panagene
• Perkin Elmer
• Primerdesign(Novacyt)
• Prominex
• Proof Diagnostics
• Qiagen
• QuantuMDx
• QuidelOrtho
• Roche Molecular Diagnostics
• Saw Diagnostics
• Scope Fluidics
• Seegene
• Siemens Healthineers
• Sona Nanotech
• SpeeDx
• T2 Biosystems
• Talis Biomedical
• Thermo Fisher Scientific Inc.
• Vela Diagnostics
• Veramarx
• Visby Medical
• XCR Diagnostics

제8장 세계 증후군 멀티플렉스 진단 시장

• 세계 시장 개요, 국가별
• 세계 시장 개요, 증후군별
• 세계 시장 개요, 장소별
• 세계 시장 개요, 제품별

제9장 세계의 증후군 멀티플렉스 시장- 증후군별

• 호흡기
• 위장
• 혈액
• 수막염/뇌염
• 성감염증
• 기타

제10장 세계 증후군 멀티플렉스 시장 - 장소별

• 병원 연구실
• 외래 검사실
• 포인트 오브 케어
• 기타

제11장 세계 증후군 멀티플렉스 시장 - 제품별

• 기기
• 카트리지
• 시약
• 기타

제12장 부록

JHS

영문 목차

영문목차

Report Overview:

Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics.

Will diagnostics replace physicians? When will Infectious Disease testing move into the Physician's Office or even the Home?

Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size out for five years and even further with a later updated report with next years numbers.

All report data is available in Excel format on request.

Table of Contents

1. Market Guides

• 1.1. Situation Analysis
• 1.2. Guide for Executives and Marketing Staff
• 1.3. Guide for Investment Analysts and Management Consultants

2. Introduction and Market Definition

• 2.1. What are Syndromic Multiplex Tests?
• 2.2. Syndromic Testing - the quiet revolution in diagnostics
  • 2.2.1. Syndromic Testing - more than Panels
• 2.3. Market Definition
  • 2.3.1. Multiplex Market Size
  • 2.3.2. Currency
  • 2.3.3. Years
• 2.4. Methodology
  • 2.4.1. Methodology
  • 2.4.2. Sources
  • 2.4.3. Authors
• 2.5. Perspective: Healthcare and the IVD Industry
  • 2.5.1. Global Healthcare Spending
  • 2.5.2. Spending on Diagnostics
  • 2.5.3. Important Role of Insurance for Diagnostics

3. Infectious Disease

• 3.1. Infections - The Big Picture
• 3.2. The Pathogens
  • 3.2.1. Bacteria
  • 3.2.2. Fungi and Protozoa
  • 3.2.3. Viruses
  • 3.2.4. Prions
• 3.3. Symptoms and Syndromes
  • 3.3.1. Bacterial or viral
  • 3.3.2. Typical Viral Symptoms
  • 3.3.3. Typical Bacterial Symptoms
• 3.4. Disease
• 3.5. Transmission
• 3.6. Infectious Disease Diagnostics
  • 3.6.1. Microbial culture
  • 3.6.2. Microscopy
  • 3.6.3. Biochemical tests
  • 3.6.4. PCR-based diagnostics
  • 3.6.5. Metagenomic sequencing
• 3.7. Defining Infections
• 3.8. Syndromic Infection

4. Industry Overview

• 4.1. Players in a Dynamic Market
  • 4.1.1. Academic Research Lab
  • 4.1.2. Diagnostic Test Developer
  • 4.1.3. Instrumentation Supplier
  • 4.1.4. Chemical/Reagent Supplier
  • 4.1.5. Pathology Supplier
  • 4.1.6. Independent Clinical Laboratory
  • 4.1.7. Public National/regional Laboratory
  • 4.1.8. Hospital Laboratory
  • 4.1.9. Physicians Office Lab (POLS)
  • 4.1.10. Audit Body
  • 4.1.11. Certification Body
• 4.2. The Clinical Laboratory Market Segments
  • 4.2.1. Traditional Market Segmentation
  • 4.2.2. Laboratory Focus and Segmentation
  • 4.2.3. Segmenting the Syndromic Testing Market
• 4.3. Industry Structure
  • 4.3.1. Hospital Testing Share
  • 4.3.2. Economies of Scale
    • 4.3.2.1. Hospital vs. Central Lab
  • 4.3.3. Physician Office Lab's
  • 4.3.4. Physician's and POCT

5. Market Trends

• 5.1. Factors Driving Growth
  • 5.1.1. Speed of Diagnosis
  • 5.1.2. Effect of Syndromic Testing on Costs
  • 5.1.3. Point of Care Advantage
  • 5.1.4. Accuracy and Diagnostic Risk
  • 5.1.5. Single Visits
  • 5.1.6. Improvement in Outcomes
  • 5.1.7. Impact of the Pandemic
• 5.2. Factors Limiting Growth
  • 5.2.1. Lower Prices
  • 5.2.2. Administration/reimbursement
  • 5.2.3. Infectious Disease is Declining But..
  • 5.2.4. Wellness Hurts
  • 5.2.5. Economic Growth improves Living Standards
  • 5.2.6. Impact of the Pandemic
• 5.3. Instrumentation, Automation and Diagnostic Trends
  • 5.3.1. Traditional Automation and Centralization
  • 5.3.2. The New Automation, Decentralization and Point of Care
  • 5.3.3. Instruments Key to Market Share
  • 5.3.4. Bioinformatics Plays a Role
  • 5.3.5. PCR Takes Command
  • 5.3.6. Next Generation Sequencing Fuels a Revolution
  • 5.3.7. NGS Impact on Pricing
  • 5.3.8. Whole Genome Sequencing, A Brave New World
  • 5.3.9. Companion Diagnostics Blurs Diagnosis and Treatment
  • 5.3.10. Comparing Syndrome and Targeted Testing
  • 5.3.11. The Multiplex Paradigm Shift
  • 5.3.12. The Sepsis Testing Market - Bellwether for Syndromics
  • 5.3.13. The Single Visit and AntiMicrobial Resistance
  • 5.3.14. Syndromics drives POCT adoption.

6. Syndromic Testing Recent Developments

• 6.1. Recent Developments - Importance and How to Use This Section
  • 6.1.1. Importance of These Developments
  • 6.1.2. How to Use This Section
• 6.2. Credo Preps MDx System, Multiplex Respiratory Test for US Launch
• 6.3. Diasorin Nabs Clearance for Expanded Respiratory Panel
• 6.4. Bosch, R-Biopharm to Invest Euro-150M in PCR Tests for Vivalytic MDx Platform
• 6.5. Cepheid Gets Waiver for Multiplex Vaginal Panel
• 6.6. BioMerieux Submits Application for Respiratory, Sore Throat Panel
• 6.7. Sensible Diagnostics Nabs Award for Respiratory Panel
• 6.8. Aptitude Medical Systems to Develop At-Home STI Test
• 6.9. Multiplex Meningitis/Encephalitis Panel Market Expanding
• 6.10. Burst Dx to Deliver Lab-Accurate ELISA-in-a-Cartridge
• 6.11. OpGen Seeking Approval for UTI Panel
• 6.12. Altratech to Enter MDx, POC Space by Supplanting PCR
• 6.13. BIOFIRE Announces New SPOTFIRE-R System
• 6.14. Cambridge Nucleomics to Develop 'Nanobait' Tech
• 6.15. Takara Bio Developing Multiplex Panels
• 6.16. Rover Diagnostics Developing Optical Multiplex PCR
• 6.17. Nanopath Secures Funding to Develop POC Dx
• 6.18. Genetic Signatures Wins Public Health Wales Contract
• 6.19. Qiagen Looks to Long-Term Growth
• 6.20. LexaGene Gets Investment
• 6.21. Seegene Multiplex COVID-19/Flu/RSV Test Receives Approval
• 6.22. BforCure to Adapt Rapid PCR Platform for Cancer
• 6.23. Accelerated Growth for Decentralized Testing
• 6.24. QuantuMDx Developing Syndromic Panels for European Launch
• 6.25. Quidel Gains CE Mark for Savanna Analyzer, Respiratory Panel
• 6.26. QuantumDx Gets CE Mark for Rapid PoC PCR System
• 6.27. Bio-Rad Laboratories, Seegene Partner for MDx Development
• 6.28. Baebies to Expand Finder Platform
• 6.29. With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio
• 6.30. Binx Health Targeting Clinics, DTC & OTC With STI Tests
• 6.31. Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV
• 6.32. Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic
• 6.33. MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test
• 6.34. New Approach Involves Silicon-Based Test for Infectious Disease Screening
• 6.35. Scanogen's Portable Battery Operated Instrument for 90 Minute Multiplex Test
• 6.36. Qiagen sees NeuMoDx as Growth Vehicle
• 6.37. Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround

7. Profiles of Key Syndromic Testing Companies

• 7.1. Abacus Diagnostica
• 7.2. Abbott Laboratories
• 7.3. Accelerate Diagnostics
• 7.4. Ador Diagnostics
• 7.5. ADT Biotech
• 7.6. Akonni Biosystems
• 7.7. Alveo Technologies
• 7.8. Antelope Dx
• 7.9. Applied BioCode
• 7.10. Aureum Diagnostics
• 7.11. Aus Diagnostics
• 7.12. Baebies
• 7.13. Beckman Coulter Diagnostics
• 7.14. Becton, Dickinson and Company
• 7.15. Binx Health
• 7.16. Biocartis
• 7.17. BioFire Diagnostics (bioMerieux)
• 7.18. bioMerieux Diagnostics
• 7.19. Bio-Rad Laboratories, Inc
• 7.20. Bosch Healthcare Solutions GmbH
• 7.21. Cepheid (Danaher)
• 7.22. Credo Diagnostics Biomedical
• 7.23. Cue Health
• 7.24. Curetis N.V. / Curetis GmbH
• 7.25. Detect
• 7.26. Diagenode Diagnostics
• 7.27. Diasorin S.p.A.
• 7.28. Domus Diagnostics
• 7.29. Enzo Biochem
• 7.30. Eurofins Scientific
• 7.31. Fluxergy
• 7.32. Fusion Genomics.
• 7.33. Genetic Signatures
• 7.34. GenMark Dx (Roche)
• 7.35. Grip Molecular Technologies
• 7.36. Hibergene Diagnostics
• 7.37. Hologic
• 7.38. Immunexpress
• 7.39. Inflammatix
• 7.40. Invetech
• 7.41. Janssen Diagnostics
• 7.42. Karius
• 7.43. Lexagene
• 7.44. LightDeck Diagnostics
• 7.45. Lucira Health
• 7.46. Luminex Corp (DiaSorin)
• 7.47. Maxim Biomedical
• 7.48. Meridian Bioscience
• 7.49. Mesa Biotech (Thermo Fisher)
• 7.50. MicroGem
• 7.51. Millipore Sigma
• 7.52. Minute Molecular
• 7.53. Mobidiag (Hologic)
• 7.54. Molbio Diagnostics
• 7.55. Nanomix
• 7.56. Novel Microdevices
• 7.57. OnsiteGene
• 7.58. Operon
• 7.59. Oxford Nanopore Technologies
• 7.60. Panagene
• 7.61. Perkin Elmer
• 7.62. Primerdesign (Novacyt)
• 7.63. Prominex
• 7.64. Proof Diagnostics
• 7.65. Qiagen
• 7.66. QuantuMDx
• 7.67. QuidelOrtho
• 7.68. Roche Molecular Diagnostics
• 7.69. Saw Diagnostics
• 7.70. Scope Fluidics
• 7.71. Seegene
• 7.72. Siemens Healthineers
• 7.73. Sona Nanotech
• 7.74. SpeeDx
• 7.75. T2 Biosystems
• 7.76. Talis Biomedical
• 7.77. Thermo Fisher Scientific Inc.
• 7.78. Vela Diagnostics
• 7.79. Veramarx
• 7.80. Visby Medical
• 7.81. XCR Diagnostics

8. The Global Market for Syndromic Multiplex Diagnostics

• 8.1. Global Market Overview by Country
  • 8.1.1. Table - Global Market by Country
  • 8.1.2. Chart - Global Market by Country
• 8.2. Global Market by Syndrome - Overview
  • 8.2.1. Table - Global Market by Syndrome
  • 8.2.2. Chart - Global Market by Syndrome - Base/Final Year Comparison
  • 8.2.3. Chart - Global Market by Syndrome - Base Year
  • 8.2.4. Chart - Global Market by Syndrome - End Year
  • 8.2.5. Chart - Global Market by Syndrome - Share by Year
  • 8.2.6. Chart - Global Market by Syndrome - Segments Growth
• 8.3. Global Market by Place - Overview
  • 8.3.1. Table - Global Market by Place
  • 8.3.2. Chart - Global Market by Place - Base/Final Year Comparison
  • 8.3.3. Chart - Global Market by Place - Base Year
  • 8.3.4. Chart - Global Market by Place - End Year
  • 8.3.5. Chart - Global Market by Place - Share by Year
  • 8.3.6. Chart - Global Market by Place - Segments Growth
• 8.4. Global Market by Product - Overview
  • 8.4.1. Table - Global Market by Product
  • 8.4.2. Chart - Global Market by Product - Base/Final Year Comparison
  • 8.4.3. Chart - Global Market by Product - Base Year
  • 8.4.4. Chart - Global Market by Product - End Year
  • 8.4.5. Chart - Global Market by Product - Share by Year
  • 8.4.6. Chart - Global Market by Product - Segments Growth

9. Global Syndromic Multiplex Markets - By Syndrome

• 9.1. Respiratory
  • 9.1.1. Table Respiratory - by Country
  • 9.1.2. Chart - Respiratory Growth
• 9.2. Gastrointestinal
  • 9.2.1. Table Gastrointestinal - by Country
  • 9.2.2. Chart - Gastrointestinal Growth
• 9.3. Blood
  • 9.3.1. Table Blood - by Country
  • 9.3.2. Chart - Blood Growth
• 9.4. Meningitis/Encephalitis
  • 9.4.1. Table Meningitis/Encephalitis - by Country
  • 9.4.2. Chart - Meningitis/Encephalitis Growth
• 9.5. Sexually Transmitted Disease
  • 9.5.1. Table Sexually Transmitted Disease - by Country
  • 9.5.2. Chart - Sexually Transmitted Disease Growth
• 9.6. Other Syndrome
  • 9.6.1. Table Other - by Country
  • 9.6.2. Chart - Other Growth

10. Global MDx Infectious Disease Markets - by Place

• 10.1. Hospital Lab
  • 10.1.1. Table Hospital Lab - by Country
  • 10.1.2. Chart - Hospital Lab Growth
• 10.2. Outpatient Lab
  • 10.2.1. Table Outpatient Lab - by Country
  • 10.2.2. Chart - Outpatient Lab Growth
• 10.3. Point of Care
  • 10.3.1. Table Point of Care - by Country
  • 10.3.2. Chart - Point of Care Growth
• 10.4. Other Place
  • 10.4.1. Table Other - by Country
  • 10.4.2. Chart - Other Place Growth

11. Global MDx Infectious Disease Markets - by Product

• 11.1. Instruments
  • 11.1.1. Table Instruments - by Country
  • 11.1.2. Chart - Instruments Growth
• 11.2. Cartridges
  • 11.2.1. Table Cartridges - by Country
  • 11.2.2. Chart - Cartridges Growth
• 11.3. Reagents
  • 11.3.1. Table Reagents - by Country
  • 11.3.2. Chart - Reagents Growth
• 11.4. Other Product
  • 11.4.1. Table Other Product - by Country
  • 11.4.2. Chart - Other Product Growth

12. Appendices

• 12.1. United States Medicare System: Clinical Laboratory Fees Schedule
• 12.2. The Most Used IVD Assays
• 12.3. The Highest Grossing Assays

관련자료